{"id":"hereditary_cancer_testing_report","version":"0.2.0","templates":[{"id":"Hereditary_Cancer_Testing_report","version":"0.1.0"}],"language":"en","updated":"2021-09-16T14:20:11+02:00","authors":[{"name":"Rong Chen","email":"rong.chen@cambio.se"}],"format":"CambioForm.v1","name":"Hereditary Cancer Testing report","actions":[{"condition":"age_group=='at0004'","assignments":["46_50_y_with_any.hidden=true","above_51y_with_1_relative.hidden=true","above_51y_with_3_diagnoses.hidden=true","above_51y_with_2_relatives.hidden=true"]},{"condition":"age_group=='at0005'","assignments":["46_50_y_with_any.hidden=false","above_51y_with_1_relative.hidden=true","above_51y_with_3_diagnoses.hidden=true","above_51y_with_2_relatives.hidden=true"],"otherwise":["age_group=='at0005'"]},{"condition":"age_group=='at0006'","assignments":["46_50_y_with_any.hidden=true","above_51y_with_1_relative.hidden=false","above_51y_with_3_diagnoses.hidden=false","above_51y_with_2_relatives.hidden=false"]},{"condition":"!age_group","assignments":["46_50_y_with_any.hidden=true","above_51y_with_1_relative.hidden=true","above_51y_with_3_diagnoses.hidden=true","above_51y_with_2_relatives.hidden=true"]}],"elements":[{"type":"form","children":[{"type":"container","children":[{"type":"row","spanlarge":12,"spanmedium":8,"spansmall":4,"children":[{"type":"column","spanlarge":12,"spanmedium":8,"spansmall":4,"children":[{"type":"text","text":"# Hereditary Cancer Testing Criteria. NCCN Guidelines Version 1.2022\n\n# \n\n\n\n## **TESTING CRITERIA FOR HIGH-PENETRANCE BREAST CANCER SUSCEPTIBILITY GENES**\n\n## **(Specifically BRCA1, BRCA2, CDH1, PALB2, PTEN, and TP53)**"}]},{"type":"column","spanlarge":6,"spanmedium":6,"spansmall":4,"children":[{"type":"input-select","label":"Age group","name":"age_group","options":[{"text":"≤ 45 y","value":"at0004"},{"text":"46-50 y","value":"at0005"},{"text":"≥ 51 y","value":"at0006"}],"clearable":true},{"type":"input-select","label":"46-50 y with ANY","name":"46-50_y_with_any","options":[{"text":"Unknown or limited family history","value":"at0008"},{"text":"Multiple primary breast cancers (synchronous or metachronous)","value":"at0009"},{"text":"≥1 close blood relative with breast, ovarian, pancreatic or prostate cancer at any age","value":"at0010"}],"clearable":true,"display":"buttons","hidden":true,"id":"46_50_y_with_any"},{"type":"input-select","label":"≥51 y with ≥1 close blood relative with ANY","name":"≥51_y_with_≥1_close_blood","options":[{"text":"Breast cancer at age ≤50 y or male breast cancer at any age","value":"at0012"},{"text":"Ovarian cancer any age","value":"at0013"},{"text":"Pancreatic cancer any age","value":"at0014"},{"text":"Metastatic, intraductal/cribriform histology, or high- or very-high risk group","value":"at0015"}],"clearable":true,"hidden":true,"id":"above_51y_with_1_relative","display":"buttons"},{"type":"input-boolean","label":"≥51 y with ≥3 total diagnoses of breast cancer in patient and/ or close blood relatives","name":"≥51_y_with_≥3_total_diagnoses","hidden":true,"id":"above_51y_with_3_diagnoses"},{"type":"input-boolean","label":"≥51 y with ≥2 close blood relatives with either breast or prostate cancer at any age","name":"≥51_y_with_≥2_close_blood","hidden":true,"id":"above_51y_with_2_relatives"},{"type":"input-select","label":"Any age","name":"any_age","options":[{"text":"To aid in systemic treatment decisions using PARP inhibitors for breast cancer in the metastatic setting","value":"at0018"},{"text":"To aid in adjuvant treatment decisions with olaparib for high-risk, HER-2 negative breast cancer","value":"at0019"},{"text":"Triple-negative breast cancer","value":"at0020"},{"text":"Lobular breast cancer with personal or family history of diffuse gastric cancer","value":"at0021"},{"text":"Male breast cancer","value":"at0022"},{"text":"≥ close blood relative with male breast cancer","value":"at0023"}],"clearable":true},{"type":"input-boolean","label":"Ashkenazi Jewish ancestry","name":"ashkenazi_jewish_ancestry"}]},{"type":"column","spanlarge":6,"spanmedium":6,"spansmall":4,"children":[{"type":"input-boolean","label":"Hereditary Cancer Testing is Clinically Indicated","name":"hereditary_cancer_testing_is"}]}]},{"type":"row","spanlarge":12,"spanmedium":8,"spansmall":4},{"type":"reset-button","label":"Reset"},{"type":"submit-button","label":"Submit","justify":"end"}]}]}]}